Alamar outlines $116M-$120M 2026 revenue outlook while targeting 100+ instruments and $400,000+ pull-through (NASDAQ:ALMR)
· seekingalpha.com
Alamar Biosciences (ALMR) Q2 2026 earnings call recap: 82% revenue growth, 60% gross margin, 2026 guidance and neurology partnerships—read the insights now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...